TY  - JOUR
A1  - Hofmann, Julian
A1  - Fayez, Shaimaa
A1  - Scheiner, Matthias
A1  - Hoffmann, Matthias
A1  - Oerter, Sabrina
A1  - Appelt‐Menzel, Antje
A1  - Maher, Pamela
A1  - Maurice, Tangui
A1  - Bringmann, Gerhard
A1  - Decker, Michael
T1  - Sterubin: Enantioresolution and Configurational Stability, Enantiomeric Purity in Nature, and Neuroprotective Activity in Vitro and in Vivo
JF  - Chemistry – A European Journal
N2  - Alzheimer′s disease (AD) is a neurological disorder with still no preventive or curative treatment. Flavonoids are phytochemicals with potential therapeutic value. Previous studies described the flavanone sterubin isolated from the Californian plant Eriodictyon californicum as a potent neuroprotectant in several in vitro assays. Herein, the resolution of synthetic racemic sterubin (1) into its two enantiomers, (R)‐1 and (S)‐1, is described, which has been performed on a chiral chromatographic phase, and their stereochemical assignment online by HPLC‐ECD coupling. (R)‐1 and (S)‐1 showed comparable neuroprotection in vitro with no significant differences. While the pure stereoisomers were configurationally stable in methanol, fast racemization was observed in the presence of culture medium. We also established the occurrence of extracted sterubin as its pure (S)‐enantiomer. Moreover, the activity of sterubin (1) was investigated for the first time in vivo, in an AD mouse model. Sterubin (1) showed a significant positive impact on short‐ and long‐term memory at low dosages.
KW  - Alzheimer′s disease
KW  - chiral resolution
KW  - circular dichroism
KW  - Eriodictyon californicum
KW  - flavonoids
KW  - sterubin
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-215993
VL  - 26
IS  - 32
SP  - 7299
EP  - 7308
ER  - 
TY  - JOUR
A1  - Appelt‐Menzel, Antje
A1  - Oerter, Sabrina
A1  - Mathew, Sanjana
A1  - Haferkamp, Undine
A1  - Hartmann, Carla
A1  - Jung, Matthias
A1  - Neuhaus, Winfried
A1  - Pless, Ole
T1  - Human iPSC‐Derived Blood‐Brain Barrier Models: Valuable Tools for Preclinical Drug Discovery and Development?
JF  - Current Protocols in Stem Cell Biology
N2  - Translating basic biological knowledge into applications remains a key issue for effectively tackling neurodegenerative, neuroinflammatory, or neuroendocrine disorders. Efficient delivery of therapeutics across the neuroprotective blood‐brain barrier (BBB) still poses a demanding challenge for drug development targeting central nervous system diseases. Validated in vitro models of the BBB could facilitate effective testing of drug candidates targeting the brain early in the drug discovery process during lead generation. We here review the potential of mono‐ or (isogenic) co‐culture BBB models based on brain capillary endothelial cells (BCECs) derived from human‐induced pluripotent stem cells (hiPSCs), and compare them to several available BBB in vitro models from primary human or non‐human cells and to rodent in vivo models, as well as to classical and widely used barrier models [Caco‐2, parallel artificial membrane permeability assay (PAMPA)]. In particular, we are discussing the features and predictivity of these models and how hiPSC‐derived BBB models could impact future discovery and development of novel CNS‐targeting therapeutics.
KW  - blood‐brain barrier (BBB)
KW  - CNS disease
KW  - drug permeability screening
KW  - human‐induced pluripotent stem cells (hiPSC)
KW  - preclinical drug discovery
Y1  - 2020
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-218509
VL  - 55
IS  - 1
ER  -